190 related articles for article (PubMed ID: 21142749)
21. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
Pope WB; Kim HJ; Huo J; Alger J; Brown MS; Gjertson D; Sai V; Young JR; Tekchandani L; Cloughesy T; Mischel PS; Lai A; Nghiemphu P; Rahmanuddin S; Goldin J
Radiology; 2009 Jul; 252(1):182-9. PubMed ID: 19561256
[TBL] [Abstract][Full Text] [Related]
22. Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Shin BJ; Burkhardt JK; Riina HA; Boockvar JA
Neurosurg Clin N Am; 2012 Apr; 23(2):323-9, ix-x. PubMed ID: 22440875
[TBL] [Abstract][Full Text] [Related]
23. Disseminated progression of glioblastoma after treatment with bevacizumab.
Bloch O; Safaee M; Sun MZ; Butowski NA; McDermott MW; Berger MS; Aghi MK; Parsa AT
Clin Neurol Neurosurg; 2013 Sep; 115(9):1795-801. PubMed ID: 23706614
[TBL] [Abstract][Full Text] [Related]
24. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
[TBL] [Abstract][Full Text] [Related]
25. Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article.
Hassaneen W; Levine NB; Suki D; Salaskar AL; de Moura Lima A; McCutcheon IE; Prabhu SS; Lang FF; DeMonte F; Rao G; Weinberg JS; Wildrick DM; Aldape KD; Sawaya R
J Neurosurg; 2011 Mar; 114(3):576-84. PubMed ID: 20690813
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab antiangiogenic therapy for glioblastoma.
Junck L
Neurology; 2011 Feb; 76(5):414-5. PubMed ID: 21282587
[No Abstract] [Full Text] [Related]
27. A review on bevacizumab and surgical wound healing: an important warning to all surgeons.
Gordon CR; Rojavin Y; Patel M; Zins JE; Grana G; Kann B; Simons R; Atabek U
Ann Plast Surg; 2009 Jun; 62(6):707-9. PubMed ID: 19461291
[TBL] [Abstract][Full Text] [Related]
28. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement.
Erinjeri JP; Fong AJ; Kemeny NE; Brown KT; Getrajdman GI; Solomon SB
Cancer; 2011 Mar; 117(6):1296-301. PubMed ID: 21381016
[TBL] [Abstract][Full Text] [Related]
29. Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab.
Blumenthal DT; Kanner AA; Aizenstein O; Cagnano E; Greenberg A; Hershkovitz D; Ram Z; Bokstein F
World Neurosurg; 2018 Feb; 110():e727-e737. PubMed ID: 29183864
[TBL] [Abstract][Full Text] [Related]
30. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM
Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944
[TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
Nagaiah G; Almubarak M; Khan M; Altaha R
Cancer Invest; 2010 Dec; 28(10):1048-53. PubMed ID: 20873990
[TBL] [Abstract][Full Text] [Related]
32. Discussion: Management of a complex scalp defect.
Serletti JM
Plast Reconstr Surg; 2008 Aug; 122(2):626-629. PubMed ID: 18626385
[No Abstract] [Full Text] [Related]
33. [Surgical management of bevacizumab-associated peritonitis due to perforation].
Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic plastic surgery closure of neurosurgical scalp incisions reduces the incidence of wound complications in previously-operated patients treated with bevacizumab (Avastin®) and radiation.
Golas AR; Boyko T; Schwartz TH; Stieg PE; Boockvar JA; Spector JA
J Neurooncol; 2014 Sep; 119(2):327-31. PubMed ID: 24872117
[TBL] [Abstract][Full Text] [Related]
35. Early assessment of recurrent glioblastoma response to bevacizumab treatment by diffusional kurtosis imaging: a preliminary report.
Lee CY; Kalra A; Spampinato MV; Tabesh A; Jensen JH; Helpern JA; de Fatima Falangola M; Van Horn MH; Giglio P
Neuroradiol J; 2019 Oct; 32(5):317-327. PubMed ID: 31282311
[TBL] [Abstract][Full Text] [Related]
36. Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.
Urup T; Staunstrup LM; Michaelsen SR; Vitting-Seerup K; Bennedbæk M; Toft A; Olsen LR; Jønson L; Issazadeh-Navikas S; Broholm H; Hamerlik P; Poulsen HS; Lassen U
BMC Cancer; 2017 Apr; 17(1):278. PubMed ID: 28420326
[TBL] [Abstract][Full Text] [Related]
37. Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme.
Eryılmaz MK; Mutlu H; Yalçin Müsri F; Salim DK; Tazegül G; Coşkun HŞ
J Oncol Pharm Pract; 2017 Jul; 23(5):392-395. PubMed ID: 27105898
[TBL] [Abstract][Full Text] [Related]
38. Outcomes in patients with recurrent/progressive glioblastoma treated with bevacizumab funded by a regional cancer drug fund.
Dixit S; Hatfield P; Clenton S; Loughrey C; Hingorani M
Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):238-9. PubMed ID: 24461951
[No Abstract] [Full Text] [Related]
39. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.
Wen PY; Schiff D; Cloughesy TF; Raizer JJ; Laterra J; Smitt M; Wolf M; Oliner KS; Anderson A; Zhu M; Loh E; Reardon DA
Neuro Oncol; 2011 Apr; 13(4):437-46. PubMed ID: 21297127
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab for glioblastoma: current indications, surgical implications, and future directions.
Castro BA; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E9. PubMed ID: 25581938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
